ReviewLiver Disease in the HIV–Infected Individual
Section snippets
Hepatitis C Virus
Most liver disease among HIV-infected individuals is secondary to coinfection with HCV and/or HBV.12 Because of shared risk factors, coinfection with HCV and HIV is common. Reported prevalence rates of HIV-HCV coinfection vary depending on the route of HIV transmission, from 10% among those with high-risk sexual behavior to 90% with injection drug use.13 Overall, approximately 30% of HIV-infected individuals in the United States and Europe are coinfected with HCV.14
HIV infection alters the
Antiretroviral Therapy–Related Medication Toxicity
Liver toxicity is one of the most common serious adverse events associated with ART.57 The clinical presentation can range from mild asymptomatic increases in serum transaminases to overt liver failure.58 In retrospective studies, the incidence of ART-related severe hepatotoxicity is approximately 10%, and life-threatening events occur at a rate of 2.6 per 100 person-years.59, 60
There are 4 primary mechanisms by which ART can lead to liver damage: direct drug toxicity and/or drug metabolism,
Alcoholic Liver Disease
Although alcoholic liver disease is responsible for nearly half of all deaths due to chronic liver disease in the United States, the role of alcohol abuse on liver disease in HIV-infected populations has not been well-defined. In one study of 2864 HIV-infected adults in the United States, 8% of the entire cohort and 15% of current alcohol drinkers were classified as heavy drinkers, which is almost twice as prevalent as in the general population.69
Active alcohol intake is known to be associated
Nonalcoholic Fatty Liver Disease
NAFLD refers to fat deposition in hepatocytes, or steatosis, in individuals with little or no alcohol use. When accompanied by inflammation and fibrosis, it is referred to as nonalcoholic steatohepatitis (NASH). The prevalence of NAFLD in the U.S. population ranges from 17%–33%, and risk factors include obesity, hyperglycemia, diabetes mellitus, and hypertriglyceridemia.73 Recently, mounting evidence suggests that the prevalence of hepatic steatosis in HIV-infected patients is high, especially
Nodular Regenerative Hyperplasia
Nodular regenerative hyperplasia (NRH) is a rare condition characterized by multiple small regenerative nodules in the liver parenchyma. NRH has recently become increasingly recognized in HIV-infected patients with cryptogenic liver disease.82 Although the etiology is unclear, both ddI use and thrombophilia have been associated with the disease.82, 83 NRH should be considered in HIV-infected patients with portal hypertension of unclear etiology, especially those on ddI.
Acquired Immunodeficiency Syndrome Cholangiopathy
AIDS cholangiopathy occurs when infection-related strictures in the biliary tract lead to biliary obstruction. It typically presents with right upper quadrant (RUQ) pain and a markedly increased alkaline phosphatase level, with less elevated bilirubin and normal or slightly increased transaminase levels. Patients might also have fever, nausea, vomiting, and diarrhea; jaundice is uncommon.84 It is usually seen in low CD4 counts (<100/mm3). Consequently, although previously relatively common
Conclusions
Liver disease among HIV-infected individuals is a common and important cause of non-AIDS–related morbidity and mortality. In the ART era, the spectrum of liver disease among patients with HIV infection has changed dramatically, shifting from opportunistic infections to sequelae of chronic infections, medication toxicities, alcohol use, and fatty liver. Management of HIV-infected patients requires recognition of these conditions and targeted diagnosis and treatment.
References (99)
- et al.
Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons
Clin Gastroenterol Hepatol
(2010) Viral hepatitis and HIV coinfection
J Hepatol
(2008)- et al.
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
J Hepatol
(1997) Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates
J Hepatol
(2006)- et al.
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy
J Hepatol
(2006) - et al.
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection
Lancet
(2003) - et al.
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study
J Hepatol
(2009) - et al.
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Lancet
(2002) - et al.
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update
Clin Gastroenterol Hepatol
(2008) - et al.
Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
Lancet
(1997)
Hyperlactataemia syndromes associated with HIV therapy
Lancet Infect Dis
Prognostic factors for the survival of patients with AIDS cholangiopathy
Am J Gastroenterol
Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease
Am J Med
Gallbladder and biliary tract disease in AIDS
Gastroenterol Clin North Am
Hepatobiliary complications in patients with human immunodeficiency virus infection
Am J Med
Diagnosis and treatment of hepatic disease in patients with HIV
Gastroenterol Clin North Am
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984–2004
AIDS
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators
N Engl J Med
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study
J Acquir Immune Defic Syndr
Group TDCoAEoA-HIVdS: factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study
AIDS
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
Clin Infect Dis
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients
AIDS Res Hum Retrovir
HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms
Clin Infect Dis
Hepatobiliary manifestations of the acquired immune deficiency syndrome
Am J Gastroenterol
Pathology of AIDS-related liver disease
Dig Dis
Management of hepatic complications in HIV-infected persons
J Infect Dis
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
Arch Intern Med
Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival
Clin Infect Dis
The natural history of hepatitis C virus infection: host, viral, and environmental factors
JAMA
The progression of HCV-associated liver disease in a cohort of haemophilic patients
Br J Haematol
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group
Hepatology
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis
Clin Infect Dis
Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
J Clin Microbiol
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection
AIDS
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection
HIV Clin Trials
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection
Clin Infect Dis
Diagnosis, management, and treatment of hepatitis C: an update
Hepatology
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Nature
Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort
Antivir Ther
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
N Engl J Med
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
JAMA
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
N Engl J Med
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
AIDS
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients
Clin Infect Dis
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
Antivir Ther
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression
Clin Infect Dis
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
J Acquir Immune Defic Syndr
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients
Antivir Ther
Cited by (149)
A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China
2023, The Lancet Regional Health - Western PacificPrevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis
2023, Clinical Gastroenterology and HepatologyConventional liver imaging in hepatitis
2023, Comprehensive Guide to Hepatitis Advances
Conflicts of interest The authors disclose no conflicts.
Funding This publication was made possible by grants 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (J.C.P.), NIH R01 AI071820 (C.L.T.), and NIH R01 AI060449 (C.L.T.). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/.